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Abstract  
Background: Inflammation, reflected by high plasma interleukin-6 concentration, is 
associated with acute kidney injury (AKI) in septic patients. Neutrophil activation has 
pathophysiological significance in experimental septic AKI. We hypothesised that neutrophil 
activation is associated with AKI in critically ill sepsis patients.     
 
Methods: We measured plasma (n=182) and urine (n=118) activin A (a rapidly released 
cytosolic neutrophil protein), interleukin-8 (a chemotactic factor for neutrophils), 
myeloperoxidase (a neutrophil biomarker released in tissues), and interleukin-6 on intensive 
care unit admission (plasma and urine) and 24 hours later (plasma) in sepsis patients 
manifesting their first organ dysfunction between 24 hours preceding admission and the 
second calendar day in intensive care unit. AKI was defined by the Kidney Disease: 
Improving Global Outcomes criteria.  
 
Results: Plasma admission interleukin-8 [240 (60-971) vs. 50 (19-164) pg/ml, p<0.001] and 
activin A [845 (554-1895) vs. 469 (285-862) pg/ml, p<0.001] were but myeloperoxidase [169 
(111-300) vs. 144 (88-215) ng/ml, p=0.056] was not higher among patients with AKI 
compared with those without. Urine admission interleukin-8 [50.4 (19.8-145.3) vs. 9.5 (2.7-
28.7) ng/ml, p<0.001] and myeloperoxidase [7.7 (1.5-12.6) vs. 1.9 (0.4-6.9) ng/ml, p<0.001] 
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were but activin A [9.7 (1.4-42.6) vs. 4.0 (0.0-33.0) ng/ml, p=0.064] was not higher in AKI 
than non-AKI patients. Urine myeloperoxidase correlated with urine interleukin-8 (R=0.627, 
p<0.001) but not with plasma myeloperoxidase (R=0.131, p=0.158). 
 
Conclusion: Interleukin-8 in plasma and urine was associated with septic AKI. Elevated 
plasma activin A indicates intravascular neutrophil activation in septic AKI. Concomitant 
plasma and urine myeloperoxidase measurements suggest neutrophil accumulation into 
injured kidneys.  
 
Editorial Comment 
Acute kidney injury in sepsis is common, however the pathophysiology behind it is still 
unclear. This prospective observational study reveals that neutrophil activation in plasma 
can be transferred to excretion of neutrophil activation products in urine, and this is linked to 
kidney injury, at least in sepsis. 
 
Introduction 
Acute kidney injury (AKI) is a common syndrome with an increasing incidence among 
hospitalized patients.1 In a recent prospective cohort of more than 15,000 patients,2 AKI was 
diagnosed in 32% of intensive care patients according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) criteria.3 Sepsis is the most common contributing factor to AKI in 
critically ill patients, but the pathophysiological mechanisms of septic AKI are still 
insufficiently understood.4 Growing evidence supports an inflammatory etiology of AKI 
instead of hypoperfusion related mechanisms.5 Recently, a unified theory of sepsis-induced 
AKI has been proposed.6 According to the theory, inflammation causes diffuse 
microcirculatory flow abnormalities and cell bioenergetic adaptive responses leading to the 
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clinical manifestation of AKI. As a reflection of a pro-inflammatory reaction, high plasma 
interleukin-6 (IL-6) concentration has been linked to septic AKI.7,8 Experimental evidence 
supports neutrophil activation in septic AKI. In AKI induced either by endotoxin or by cecal 
ligation and puncture, neutrophils have been demonstrated to infiltrate the kidney. Vice 
versa, neutrophil depletion and interventions reducing renal neutrophil accumulation protect 
from AKI.9-14 Neutrophil infiltration correlates with the degree of deterioration of renal 
function.10 
 
Activin A is a member of transforming growth factor-β superfamily.15 It is a 25 kD homodimer 
with a disulfide bridge. Along its numerous other functions, activin A possesses both pro- 
and anti-inflammatory properties in innate immunity. In experimental endotoxemia, serum 
activin A concentration rises within one hour after lipopolysaccharide (LPS) challenge 
simultaneously with tumor necrosis factor-α and earlier than interleukins 1β and 6.16-18 
Neutrophils, in which preformed activin A is located in the cytosol, are the main source of 
rapidly released activin A.15,19-21 Neutrophils are not only the source but also the target of 
activin A, because activin A enhances neutrophilic phagocytic function and oxidative burst.22 
In critically ill sepsis patients, and in patients with acute respiratory failure, increased serum 
activin A concentration is associated with disease severity.23-25 Interleukin-8 (IL-8) is a 
chemokine involved in neutrophil activation during inflammation. It is a strong chemotactic 
factor for neutrophils and induces their priming activity in septic patients.26-28 Neutrophil-
derived oxygen free radicals and proteases have pathophysiological significance in 
endotoxin-induced septic AKI.29 Renal neutrophil accumulation is accompanied with 
increased renal myeloperoxidase (MPO) activity, indicating that sequestered neutrophils 
release their cytotoxic contents in the renal interstitium12-13. 
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The aim of this study was to gain knowledge of the proposed inflammatory mechanisms, 
especially neutrophil activation, underlying septic AKI. We hypothesized that activin A as a 
readily released cytosolic protein of neutrophils, IL-8 as a strong endogenous chemotactic 
factor for neutrophils, and MPO as a biomarker of neutrophil azurophilic granules would be 
associated with sepsis-induced AKI among critically ill adult patients. 
 
Methods 
Reporting is in accordance with the STROBE statement on reporting observational cohort 
studies. 
 
Patients 
We studied a subgroup of adult intensive care unit (ICU) patients with severe sepsis from the 
prospective FINNAKI (FINNish Acute Kidney Injury) study, which included all eligible ICU 
patients from 17 Finnish ICUs between September 2011 and February 2012. The inclusion 
and exclusion criteria for this study are outlined in the original report.30 The FINNAKI study 
patients were screened for severe sepsis, defined by the American College of Chest 
Physicians/Society of Critical Care Medicine criteria,31 on admission and throughout the first 
five days of intensive care. Plasma samples were collected from the whole FINNAKI study 
period. Centrifuged urine samples were available from the last three months of the study. To 
detect early events of inflammation, we evaluated 237 consecutive patients who fulfilled the 
criteria for severe sepsis within 24 hours preceding ICU admission, during the admission day 
(D0), or the first complete calendar day (D1) in the ICU. To ensure the availability of urine 
samples in addition to plasma samples, the consecutive collection of the patients was 
started from the end of the FINNAKI study period backwards. We excluded patients with 
chronic kidney disease (glomerular filtration rate less than 60ml/min/1.73m2) and those 
without both admission and 24 h plasma samples available (Figure 1). The Ethics 
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Committee of the Department of Surgery in Helsinki University Hospital gave a nationwide 
approval for the FINNAKI study. To avoid delay in taking the first sample, the Ethics 
Committee granted a deferred consent policy. This was later confirmed by a written consent 
of the patient or his/her proxy.   
 
Blood and urine samples 
Blood samples were drawn from the peripheral arterial cannula into 
ethylenediaminetetraacetic acid tubes at the time of admission to the ICU (“0 hours”) and 24 
hours later (“24 hours”). The urine samples were collected at the time of admission to the 
ICU (“0 hours”). Plasma and urine samples were centrifuged and aliquoted immediately after 
ICU admission or at 2 hours at the latest, and stored at –80 °C until assayed. Including 
aliquoting and analyses, the plasma samples were thawed maximum of three times and 
urine samples maximum of two times. We used commercial enzyme-linked immunosorbent 
assay (ELISA) kits for activin A (Quantikine, R&D Systems, Abingdon, UK; detection limit 4 
pg/ml), IL-8 (Cymax, Abfrontier, Seoul, South-Korea; detection limit 0.3 pg/ml), IL-6 
(DiaClone, Besancon, France; detection limit 2 pg/ml), and MPO (BioLegend Inc., San 
Diego, CA, USA; detection limit 28 pg/ml) analyses. All plasma and urine samples were 
assayed in duplicate according to the manufacturer's instructions.     
 
Clinical data 
The clinical data were prospectively collected using a standardized case report form (CRF) 
filled daily by the attending clinician. The chronic and present health status, criteria for 
severe sepsis and septic shock, sepsis-related organ dysfunction, and information on 
administered renal replacement therapy (RRT) were recorded. The CRF data also contained 
the lowest and/or highest values (indicated as “minimum” or “maximum” in the results 
section) of predetermined laboratory tests, i.e. leukocyte count, C-reactive protein (CRP), 
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platelet count, international normalised ratio (INR), pH, base excess, and plasma lactate for 
the period of 24 hours prior to ICU admission, including the time of ICU admission. 
Physiologic data including Acute Physiology and Chronic Health Evaluation II (APACHE II), 
Simplified Acute Physiology Score II (SAPS II), urinary output, and Sequential Organ Failure 
Assessment (SOFA) scores of the first five days of ICU stay were collected from the 
database of the Finnish Intensive Care Consortium maintained by Tieto Ltd, Helsinki, 
Finland as described in the original report.30  
 
AKI was defined and classified into three stages, according to the KDIGO criteria, by 
changes in serum creatinine and urine output.3 Urine output was measured hourly and 
serum creatinine daily. The last available serum creatinine value from the preceding year up 
to one week before admission to intensive care was used as the baseline value for each 
patient. If not available, the baseline creatinine value was estimated using the Modification of 
Diet in Renal Disease equation assuming a glomerular filtration rate of 75 ml/min/1.73 m².32 
We screened for the presence of AKI throughout the first five days of ICU stay, and the 
highest stage was chosen for the final KDIGO stage of each study patient.   
 
Statistical analysis 
The study patients were staged a priori according to the KDIGO classification. Because 
activin A, IL-8, IL-6, and MPO plasma concentrations were not normally distributed, we used 
non-parametric tests. To estimate sample size for the present study, we utilized previous 
clinical data of septic AKI reporting approximately 3-fold plasma IL-6 concentrations in 
patients with AKI compared with those without AKI8 and unpublished plasma IL-6 
concentration data from a pilot study of 32 severe sepsis patients from our laboratory 
showing a 2-fold increase. As a result, when using the distribution of our pilot study and 
taking into account the non-normal distribution of plasma IL-6, a minimum of 60 
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patients/group would have been needed to achieve 80% power in detecting a 2.5-fold 
increase in plasma IL-6 concentration between AKI and non-AKI patients. We decided to 
enlarge our cohort to approximately 90 patients per group for analyses of plasma activin A, 
IL-8, and MPO without previous data available for power estimations.  
 
We conducted logistic regression analysis to test if comorbidities or disease severity 
contributed to AKI, entering all covariates at the same time, not stepwise. To compare 
groups, we used chi-square or Fisherʼs exact test for categorical variables and Mann-
Whitney U test for continuous variables. For comparisons between KDIGO stages 1-3, we 
conducted Kruskal-Wallis test and took multiple comparisons into account by using pairwise 
comparison as a post-hoc test. We illustrated diagnostic accuracy with areas under the 
curve of the receiver operating characteristic (AUCs). Recently, a definition of “severe” AKI 
comprising of KDIGO stages 2 and 3 has been applied in biomarker studies.33,34 
Consequently, we calculated AUCs for both the original KDIGO AKI definition (i.e. stages 1-3 
vs. stage 0) and KDIGO criterion of a “severe” AKI (i.e. stages 2-3 vs. stages 0-1). We 
applied Bonferroni correction when comparing the two time points in patients with KDIGO 
stages 0-3, and a p value <0.0125 was considered significant. Otherwise, a p value <0.05 
was considered significant. The data are expressed as counts and percentages or as 
medians with interquartile ranges (IQR), and AUCs are given with 95% confidence intervals. 
Statistical analyses were conducted using SPSS 22 software (SPSS Inc., Chicago, IL, USA). 
 
Results 
Patients 
Figure 1 presents the study flow chart. We included 182 patients, of whom 97 (53%) fulfilled 
severe sepsis criteria on admission and 85 (47%) during the day of ICU admission (D0) or 
the following day (D1), illustrated in Figure S1 in the supplements. The patient 
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characteristics and the clinical outcomes of all 182 patients are presented in Table 1. AKI 
was diagnosed in 92 of 182 (51%) patients (Figure 1, Table 1), of whom 50 (54%) were 
diagnosed with AKI on ICU admission day (D0), 35 (38%) on day 1 and 7 (7.6%) on days 2-
4. Of 92 patients with AKI, 37 (40%) had KDIGO stage 1, 19 (21%) stage 2 and 36 (39%) 
stage 3 AKI. The time of fulfilling KDIGO AKI criteria in relation to ICU admission is shown in 
Figure S2. 26 (14 %) patients commenced RRT in the ICU. A history of hypertension and 
septic shock were more frequent among patients with AKI than in those without. AKI patients 
had higher maximum SOFA score even if renal points were subtracted (Table 1). Of age, 
gender, co-morbidities, admission type and disease severity variables in table 1, only 
diabetes, systolic heart failure and maximum SOFA score without renal points were 
associated with AKI. 
 
Plasma measurements 
We analysed IL-6 and MPO from both 0 h and 24 h plasma samples of all 182 patients. IL-8 
was analysed of 180 patients and activin A of 179 patients due to insufficient samples from a 
few study patients. The measured laboratory parameters in plasma at 0 and 24 hours 
according to the presence or absence of AKI are presented in Table 2. Activin A, IL-8, and 
IL-6 were higher in AKI than in non-AKI patients at both time points (p≤0.001 for all). MPO 
was higher in patients with AKI than in those without at 24 hours but not at 0 hours. 
Leukocyte count and CRP value did not differ between AKI and non-AKI patients. 
 
Activin A, IL-8, IL-6, and MPO at both time points (0 h and 24 h) according to KDIGO stage 
are presented in Figure 2. Activin A concentration was higher in patients with KDIGO stage 3 
than stage 1 at both time points. IL-8 and MPO levels were higher in KDIGO stage 3 than in 
stage 1 at 24 hours but not at 0 hours. AUCs for AKI were better for plasma activin A [0.706 
(0.630-0.782)] and IL-8 [0.710 (0.634-0.785)] than for IL-6 [0.644 (0.562-0.725)] or MPO 
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[0.566 (0.482-0.650)], and did not improve with the outcome “severe” (=KDIGO 2-3) AKI 
(Table S1).  
 
Urine measurements 
Urine samples on ICU admission were available in 118 patients. The correlations between 
the plasma and urine concentrations of activin A, IL-8 and IL-6 were weak (R=0.335–0.415, 
all p<0.001). Urine MPO did not correlate with plasma MPO (R=0.131, p=0.158). Urine MPO 
correlated with urine IL-8 (R=0.627, p<0.001, Figure S3 of the supplementary material). 
Urine IL-8, IL-6 and MPO were higher in AKI than in non-AKI patients (p<0.001 for all, Table 
2), but there was no difference in activin A levels between the groups (Table 2). Urine activin 
A, IL-8, IL-6, and MPO at 0 hours according to KDIGO stage are presented in Figure 3. IL-8 
levels were higher in KDIGO stage 3 than in stage 1. In urine, IL-8 had the highest AUCs 
[0.765 (0.677-0.852) for AKI and 0.827 (0.749-0.905) for “severe” AKI], followed by MPO, IL-
6, and activin A  (Table S1). 
 
Discussion 
In this post-hoc analysis we evaluated the association between AKI and biomarkers 
indicating neutrophil activation in a cohort of critically ill adult patients with sepsis. We found 
that activin A and IL-8 in plasma, and MPO and IL-8 in urine were associated with septic 
AKI.  
 
We found plasma activin A concentrations comparable to previous studies.23 Plasma activin 
A was associated with septic AKI both at 0 and 24 hours. Among AKI patients, activin A 
differed according to severity of AKI already at 0 hours. Previously, activin A has been 
observed to correlate with the disease severity and mortality in septic patients.23 To our 
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knowledge, plasma IL-8 in the evolution of septic AKI has not been previously investigated. 
Of the studied AKI markers of the present study, IL-8 had the strongest association with 
septic AKI when measured in plasma or urine on admission. IL-8 levels differed between 
KDIGO stages of AKI. These data are in line with a previous study on pediatric cardiac 
surgical patients showing that IL-8 was more strongly associated with AKI than IL-6.36  
 
In sepsis, IL-8 primes neutrophils for enhanced production of reactive oxygen 
species.26Despite this, plasma MPO, a traditional biomarker of neutrophil activation, was 
only modestly higher in AKI patients than in non-AKI patients at 24 hours after ICU 
admission, but not on admission. Plasma interleukin concentrations reflect systemic 
activation of inflammation. Plasma neutrophil biomarker concentrations indicate systemic 
neutrophil activation in the intravascular space. Activin A, which is located in the neutrophil 
cytosol, is rapidly released to plasma upon neutrophil activation.15,19-21 On the contrary, 
MPO-containing azurophilic granules show the lowest propensity to degranulate in the 
intravascular space.37 The discriminative performance of MPO (with an AUC of 0.57) was 
seemingly weaker than that (AUC 0.85 to 0.88) previously reported for heparin binding 
protein (HBP), a granule protein of the neutrophilic secretory vesicles.33,34 Secretory vesicles 
are released upon neutrophil adhesion on the endothelium, i.e. while still in the intravascular 
space. MPO is mainly released after neutrophil extravasation in the tissues.37 Apparently, 
neutrophil biomarkers in plasma seem to differ substantially in their performance to reflect 
intravascular neutrophil activation.  
 
Biomarker concentrations in urine are a combined result of their release from the renal 
parenchyma and the renal excretion of the circulating plasma pool of the biomarker. 
Comparison of the urinary biomarker concentrations with concomitant plasma concentrations 
may give some hints of the phenomena occurring in the kidney itself. Such a comparison, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
however, is not straightforward. Proteinuria and oliguria, two attributes of AKI, most likely 
have a tendency to increase the observed urine concentration of the biomarker. There were 
modest correlations between the plasma and urine concentrations of activin A, IL-8 and IL-6. 
Interestingly, urinary MPO did not correlate with plasma MPO. This suggests that plasma 
MPO is not a major determinant of urinary MPO concentrations. This, in turn, may imply that 
urine MPO reflects the MPO released in the renal parenchyma. Urine MPO level not only 
associated with AKI but also correlated with urine IL-8 level. As IL-8 is a strong endogenous 
chemotactic factor for neutrophils26,27 and MPO is released first and foremost in the 
tissues,37 we suggest that renal accumulation of neutrophils may be associated with septic 
AKI. The present findings are in accordance with previous experimental findings. Increased 
renal MPO activity accompanied experimental AKI induced by endotoxemia or cecal ligation 
and puncture.12-13  
 
Our study has some limitations. First, because maximum SOFA score without renal points 
was independently associated with AKI, plasma biomarkers may reflect disease severity in 
general instead of AKI specifically. This fact, however, does not rule out pathophysiological 
significance of sequestration of systemically activated neutrophils in the kidney. Second, we 
evaluated only patients who fulfilled the criteria for severe sepsis close to ICU admission. 
Considering the rapid kinetics of neutrophil activation, this enabled us to minimise the 
confounding effect of the disease phase to the results. However, a substantial proportion of 
patients presented with AKI already before or during the sampling period. Thus, our findings 
do not enable calculations of true predictive values of the studied biomarkers regarding 
developing AKI. Third, the present subgroup of patients was comparable with the larger 
severe sepsis subgroup of the FINNAKI cohort in all respects except in slightly lower median 
age [62 (52-72) vs. 65 (55-75) years] and longer length of ICU stay [4.6 (2.7-8.0) vs. 4.0 
(1.9-7.3) days].39 By excluding patients without both 0 h and 24 h plasma samples available 
we probably excluded some patients who died during the first 24 hours in the ICU. This 
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could explain the longer ICU length of stay in our subgroup. However, the excluded patients 
did not differ from the included individuals in terms of co-morbidities and disease severity 
(Table S2 of the supplementary material). Consequently, we believe that the patients of the 
present study are a representative sample of a larger unselected severe sepsis cohort of 
adult patients admitted to ICUs nationwide, which increases the generalisability of our 
results. 
 
Conclusion 
IL-8 was associated with septic AKI both in plasma and urine in critically ill adults. Elevated 
plasma activin A in patients with AKI suggests an association of intravascular neutrophil 
activation with septic AKI. Based on concomitant plasma and urine MPO measurements, this 
may lead to accumulation and activation of neutrophils in the kidneys, and development of 
AKI.  
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Table 1. Patient characteristics and clinical outcome by acute kidney injury (AKI).  
Data were available in all 182 patients and are expressed as median [IQR] or count (%). 
 
 No AKI (n=90) AKI (n=92) p value  
Age, median [IQR] 61 [47.8-72] 64.5 [55-72] 0.058 
Male gender, n (%) 60 (66.7) 55 (59.8) 0.418 
Co-morbidities    
Hypertension, n (%) 34/89 (38.2) 53/91 (58.2) 0.012 
Diabetes, n (%) 14/90 (15.6) 25/92 (27.2) 0.084 
Atherosclerosis, n (%) 5/89 (5.6) 12/91 (13.0) 0.191 
Systolic heart failure, n (%) 9/88 (10.2) 4/91 (4.4) 0.336 
Admission type     
Emergency, n (%) 89 (98.9) 90 (97.8) 1.000 
Operative, n (%) 20/90 (22.2) 21/91 (23.1) 1.000 
Disease severity    
SAPS II, without age and renal 
components, median [IQR] 
24.5 [19-36] 26 [21-35] 0.618 
Septic shock, n (%) 56 (62.2) 75 (81.5) 0.006 
SOFA, maximum without renal 
points, median [IQR] 
8 [5.8-10] 10 [7-11] 0.007 
ICU length of stay in days, 
median [IQR] 
4.6 [2.5-7.9] 4.4 [2.8-8.1] 0.609 
90-day mortality, n (%) 21 (23.3) 27 (29.3) 0.452 
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Table 2. Biomarkers according to the presence or absence of acute kidney injury 
(AKI).  
Data are expressed as median [IQR]. * p<0.05; ** p<0.01; *** p≤0.001, 24 h vs. 0 h. 
Urine was available in 118 patients. Minimum leukocyte count and maximum CRP values for 
the period of 24 hours prior to admission to intensive care unit, including the time of 
admission, were available in 160 and 172 patients, respectively. 
 
 All  No AKI (n=90) AKI (n=92) AKI vs. no AKI
Activin A 
(pg/ml) 
Plasma 0 h  661 [368-1287] 469 [285-862] 845 [554-1895] p<0.001 
Plasma 24 h  563 [389-
1060]*** 
470 [301-827] 795 [433-
1363]** 
p<0.001 
Urine 0 h 7.1 [0.0-41.1] 4,0 [0.0-33.0] 9.7 [1.4-42.6] p=0.064 
IL-8 
(pg/ml) 
Plasma 0 h  101 [30-673] 50 [19-164] 240 [60-971] p<0.001 
Plasma 24 h  47 [20-120]*** 32 [13-74]*** 79 [31-219]*** p<0.001 
Urine 0 h 23.5 [6,9-95,5] 9.5 [2,7-28,7] 50.4 [19,8-
145,3] 
p<0.001 
IL-6 
(pg/ml) 
Plasma 0 h  203 [53-947] 109 [38-366] 402 [73-2148] p=0.001 
Plasma 24 h 101 [31-278]*** 52 [0-143]*** 182 [67-696]*** p<0.001 
Urine 0 h 48.6 [20.6-80.7] 37.8 [11.4-67.2] 67.7 [28.7-
147.9] 
p<0.001 
MPO 
(ng/ml) 
Plasma 0 h  151 [100-248] 144 [88-215] 169 [111-300] p=0.059 
Plasma 24 h 167 [110-261]* 132 [103-211] 207 [136-323]** p<0.001 
Urine 0 h 3.9 [1.0-10.5] 1.9 [0.4-6.9] 7.7 [1.5-12.6] p<0.001 
B-Leukocytes min (E9/l) 10.3 [5.5-15.6] 9.2 [5.4-13.5] 11.4 [6.1-16.1] p=0.19 
P-CRP max (mg/l) 163 [61-259] 122 [49-256] 173 [102-267] p=0.11 
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Figure legends 
 
Figure 1. Study flow chart.  
 
Figure 2. Plasma activin A, interleukin-8 (IL-8), interleukin-6 (IL-6), and 
myeloperoxidase (MPO) on admission to intensive care unit (0 h) and 24 hours 
thereafter (24 h) in patients without AKI (white bars), stage 1 (the lightest grey bars), 
stage 2 (grey bars), and stage 3 AKI (the darkest grey bars).  
*, p< 0.01 and **, p<0.005, 0 h vs. 24 h in the Mann-Whitney test with the Bonferroni 
corrected significance level of p<0.0125.  
#, p<0.05 and ##, p<0.01, KDIGO grade 1 vs. KDIGO grade 3 in the Kruskal-Wallis test with 
pairwise comparison as the post hoc test.  
 
Figure 3. Urine activin A, interleukin-8 (IL-8), interleukin-6 (IL-6), and myeloperoxidase 
(MPO) on admission to intensive care unit in patients without AKI (white bars), stage 1 
(the lightest grey bars), stage 2 (grey bars), and stage 3 AKI (the darkest grey bars). 
##, p<0.01, KDIGO grade 1 vs. KDIGO grade 3 in the Kruskal-Wallis test with pairwise 
comparison as the post hoc test.    
 
Figure S1. Time from ICU admission to the development of the first organ 
dysfunction.  
Negative value denotes that the organ dysfunction has occurred before admission. 
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Figure S2. Time from ICU admission to the diagnosis of AKI.  
One patient, who developed AKI 13.3 hours before admission to ICU, is left out of the figure 
as an outlier.    
 
Figure S3. Ln of urine MPO plotted against ln of urine IL-8 (R=0.627, p<0.001 in 
Spearman's correlation test).  
KDIGO 0 (white), KDIGO 1 (light grey), KDIGO 2 (dark grey) and KDIGO 3 (black). 
Zero values (IL-8: 8 patients and MPO: 2 patients) are replaced with a value 0.01 for 
logarithmic transformation. 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
  
